Does oncocalyxone A inhibit human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein?
OncoA showed anti-aggregatory activity in platelets that was associated with increased cGMP levels, not dependent on NO and with blocking GP Ibalpha glycoprotein. This new mechanism has the prospect of leading to new anti-thrombotic drugs.
PCI and fibrinolysis are equally beneficial in smokers with STEMI and short time to treatment.